Biggest News Aggregation in the World
📰 Open Label Phase News

Page 2 - Open Label Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Open Label Phase. Real-time updates on events, politics, business and more.

Late-Breaking Clinical Trial outcomes from The VEINS Conference: CLOUT Registry, VIVID Trial, DEXTERITY-AFP Trial, and Venous Thromboembolism Treatment

Four late-breaking clinical trial outcomes from The VEINS Conference presented results from the CLOUT Registry, VIVID Trial, DEXTERITY-AFP Trial, and Venous Thromboembolism Treatment were present during the The VEINS Conference, taking place Oct. 28-30 in Las Vegas, NV.
United States Georgia General Mahmood Razavi Jay Mathews Las Vegas Davidj Dexter

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress - Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)
United States Hidradenitis Suppurativa Jim Lee Exchange Commission European Academy Of Dermatology Group Vice

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...
United States Jim Lee Hidradenitis Suppurativa Free Communications Exchange Commission Us Food Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ipsen Pharma: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

Supplemental New Drug Application (sNDA) submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few
France General United Kingdom United States San Francisco T Ai Pei Elizabeth Kalina

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

Supplemental New Drug Application submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few... | June 14, 2023
San Francisco United States T Ai Pei France General United Kingdom Ipsen Euronext

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science